Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07783542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 2 → 15 locations Start date changed from estimate of Aug 20, 2026 to Aug 21, 2026 · Eligibility criteria expanded, about 5 words · Study description expanded, about 4 words Show 3 more changesShow less
    • Start date changed from estimate of Aug 20, 2026 to Aug 21, 2026
    • Eligibility criteria expanded, about 5 words
    • Study description expanded, about 4 words
  2. Recruitment opened Study sites: 1 to 2v2 Show 1 more changeShow less
    • Study sites: 1 to 2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
Trial Details
NCT Number NCT07783542
Lead Sponsor Oruka Therapeutics, Inc.
Conditions Hidradenitis Suppurativa (HS)
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov